Copyright
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. Jul 24, 2025; 16(7): 106107
Published online Jul 24, 2025. doi: 10.5306/wjco.v16.i7.106107
Published online Jul 24, 2025. doi: 10.5306/wjco.v16.i7.106107
Optimizing neoadjuvant chemoradiation in resectable and borderline resectable pancreatic cancer: Evidence-based insights
Gautam Sarma, Partha P Medhi, Department of Radiation Oncology, All India Institute of Medical Sciences, Guwahati 781101, Assam, India
Hima Bora, Department of Radiation Oncology, Tezpur Medical College and Hospital, Tezpur 784010, Assam, India
Author contributions: Sarma G intellectual content definition; Bora H performed data collection and manuscript editing, literature search, and drafted the manuscript; Sarma G and Medhi PP performed manuscript review and final approval; and all authors thoroughly reviewed and endorsed the final manuscript.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Hima Bora, Researcher, Department of Radiation Oncology, Tezpur Medical College and Hospital, NH-15, Tezpur 784010, Assam, India. himabora36@gmail.com
Received: February 17, 2025
Revised: April 16, 2025
Accepted: June 3, 2025
Published online: July 24, 2025
Processing time: 155 Days and 17.8 Hours
Revised: April 16, 2025
Accepted: June 3, 2025
Published online: July 24, 2025
Processing time: 155 Days and 17.8 Hours
Core Tip
Core Tip: Recognized from its inception as a systemic disease, localized pancreatic cancer is currently treated with adjuvant chemotherapy and surgical excision to improve survival rates. However, the main obstacle that may postpone or prevent the prompt delivery of adjuvant therapy is the high morbidity and delayed recovery that follows large surgical excision. Thus, acknowledging the potential of neoadjuvant chemoradiation in improving long-term survival and the chance of successful resection for a variety of digestive tract cancers, such as rectal, gastric, and oesophagal cancers, researchers have focused on investigating its potential benefits in the context of both resectable and borderline resectable pancreatic cancer.